News

Large unusual trading volume in Pfizer put options that expire 30 days from now signals investors' bullish outlook on PFE ...
If your physician prescribes a new branded drug, though, you and your insurance company have few options. Patent-protected ...
Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...
Pfizer (PFE) closed at $25.32 in the latest trading session, marking a +1.12% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.48% for the day. Elsewhere, the Dow ...
Pfizer’s shares (currently trading at $24.29) have posted a disappointing 8.5% loss while the S&P 500 was flat. This may have ...
Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential ...
Regardless of which you choose, Pfizer's (NYSE: PFE) share price has declined during the period. Pfizer's dismal stock performance in recent years underscores the challenges the big drugmaker faces.
Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely reflecting existing concerns.
The latest price target for Pfizer (NYSE:PFE) was reported by UBS on April 30, 2025. The analyst firm set a price target for $25.00 expecting PFE to rise to within 12 months (a possible 3.48% ...